Literature DB >> 17109389

Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.

Shinichi Kako1, Yoshinobu Kanda, Tomohiko Sato, Susumu Goyama, Naohiro Noda, Eriko Shoda, Kumi Oshima, Morihiro Inoue, Koji Izutsu, Takuro Watanabe, Toru Motokura, Shigeru Chiba, Masashi Fukayama, Mineo Kurokawa.   

Abstract

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder characterized by a proliferation mainly of mature neutrophils. The prognosis is generally poor and an optimal therapeutic strategy remains to be determined. Allogeneic hematopoietic stem cell transplantation (HSCT) is expected to be the only curative therapy so far. We report a 46-year-old male with progressive CNL who underwent bone marrow transplantation from an HLA-matched unrelated donor. After engraftment was achieved on day 35, relapse of CNL was confirmed on day 50. The progression of CNL was very rapid afterward and infiltration to the central nervous system was observed. The Janus Kinase 2 (JAK2) V617F homozygous mutation was detected from the peripheral blood or bone marrow samples throughout the clinical course. From comparison with reports of successful HSCT for CNL in the literature, it was inferred that HSCT should be performed in a stable status before progression. Furthermore, JAK2 V617F-positive CNL may contain an aggressive disease entity in contrast to previous reports. Accumulation of experiences is required to establish a definite role of HSCT in the treatment of CNL and a prognostic significance of JAK2 mutation in CNL. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17109389     DOI: 10.1002/ajh.20805

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report.

Authors:  Patrícia Rocha Silva; Cristina Ferreira; Susana Bizarro; Nuno Cerveira; Lurdes Torres; Ilídia Moreira; José Mário Mariz
Journal:  Oncol Lett       Date:  2015-04-24       Impact factor: 2.967

Review 2.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Chronic Neutrophilic Leukemia with V617F JAK2 Mutation.

Authors:  Smeeta Gajendra; Ritu Gupta; Meenal Chandgothia; Lalit Kumar; Richa Gupta; Snehal Motilal Chavan
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-25       Impact factor: 0.900

Review 4.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

5.  [The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia].

Authors:  Y J Cui; Q Jiang; J Q Liu; B Li; Z F Xu; T J Qin; Y Zhang; W Y Cai; H L Zhang; L W Fang; L J Pan; N B Hu; S Q Qu; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-01-14

Review 6.  Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Authors:  Argiris Symeonidis; Spiros Chondropoulos; Evgenia Verigou; Vasileios Lazaris; Alexandra Kourakli; Panagiotis Tsirigotis
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 7.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

8.  Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation.

Authors:  Shinsaku Imashuku; Naoko Kudo; Kagekatsu Kubo; Katsuyasu Saigo; Nanako Okuno; Kaoru Tohyama
Journal:  J Blood Med       Date:  2012-12-05

Review 9.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.